PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33160017-0	2021	The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion.	empagliflozin	20-33	NLR family pyrin domain containing 3	Homo sapiens	155-160	
33160017-6	2021	Importantly, SMC express SGLT2, and pre-treatment with EMPA attenuated IL-17A/TRAF3IP2-dependent oxidative stress, NLRP3 expression, caspase-1 activation, IL-1beta and IL-18 secretion, and SMC proliferation and migration.	empagliflozin	55-59	NLR family pyrin domain containing 3	Homo sapiens	115-120	
32358544-3	2020	Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity.	empagliflozin	43-56	NLR family pyrin domain containing 3	Homo sapiens	60-65